Monopar Therapeutics (MNPR) Competitors $78.44 -1.70 (-2.12%) As of 12:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. SRPT, OCUL, DYN, ANIP, VERA, TLRY, TWST, COGT, GPCR, and BHVNShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Sarepta Therapeutics (SRPT), Ocular Therapeutix (OCUL), Dyne Therapeutics (DYN), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Tilray Brands (TLRY), Twist Bioscience (TWST), Cogent Biosciences (COGT), Structure Therapeutics (GPCR), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Sarepta Therapeutics Ocular Therapeutix Dyne Therapeutics ANI Pharmaceuticals Vera Therapeutics Tilray Brands Twist Bioscience Cogent Biosciences Structure Therapeutics Biohaven Monopar Therapeutics (NASDAQ:MNPR) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Is MNPR or SRPT more profitable? Monopar Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.34%. Sarepta Therapeutics' return on equity of -1.03% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -41.76% -39.49% Sarepta Therapeutics -2.34%-1.03%-0.37% Do insiders and institutionals hold more shares of MNPR or SRPT? 1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 20.5% of Monopar Therapeutics shares are owned by insiders. Comparatively, 7.6% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher earnings & valuation, MNPR or SRPT? Sarepta Therapeutics has higher revenue and earnings than Monopar Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.33-23.55Sarepta Therapeutics$1.90B1.18$235.24M-$0.87-26.43 Which has more risk & volatility, MNPR or SRPT? Monopar Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Does the media favor MNPR or SRPT? In the previous week, Monopar Therapeutics had 1 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 8 mentions for Monopar Therapeutics and 7 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.07 beat Monopar Therapeutics' score of 0.45 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate MNPR or SRPT? Monopar Therapeutics presently has a consensus target price of $105.67, suggesting a potential upside of 34.72%. Sarepta Therapeutics has a consensus target price of $34.42, suggesting a potential upside of 49.69%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00Sarepta Therapeutics 7 Sell rating(s) 14 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.03 SummarySarepta Therapeutics beats Monopar Therapeutics on 8 of the 15 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$483.94M$3.46B$6.16B$10.68BDividend YieldN/A2.27%5.72%4.83%P/E Ratio-23.5523.2329.4127.19Price / SalesN/A470.03583.00131.55Price / CashN/A45.2825.8230.35Price / Book8.7010.4712.376.66Net Income-$15.59M-$52.71M$3.32B$276.55M7 Day Performance-23.14%4.16%1.88%0.64%1 Month Performance23.93%15.10%8.15%3.60%1 Year Performance1,326.09%13.43%60.80%36.54% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics3.1739 of 5 stars$78.44-2.1%$105.67+34.7%+1,356.9%$483.94MN/A-23.5510Gap UpSRPTSarepta Therapeutics4.6166 of 5 stars$21.96-0.7%$34.42+56.7%-82.3%$2.16B$1.90B-25.241,372OCULOcular Therapeutix4.2571 of 5 stars$11.85+0.6%$22.63+90.9%+4.5%$2.05B$63.72M-9.26230Analyst RevisionDYNDyne Therapeutics3.2771 of 5 stars$14.03-0.1%$34.07+142.8%-53.5%$2.00BN/A-3.63100Positive NewsGap UpANIPANI Pharmaceuticals3.8578 of 5 stars$88.61-1.3%$99.14+11.9%+57.2%$1.95B$614.38M-115.08600VERAVera Therapeutics2.6646 of 5 stars$30.49+1.3%$63.00+106.6%-24.1%$1.92BN/A-8.5240Gap UpTLRYTilray Brands3.2867 of 5 stars$1.69-1.7%$2.00+18.3%-1.9%$1.89B$821.31M-0.742,842TWSTTwist Bioscience3.8278 of 5 stars$30.14-3.4%$48.50+60.9%-40.0%$1.88B$312.97M-20.79990Gap UpCOGTCogent Biosciences1.8779 of 5 stars$16.20-0.4%$20.00+23.5%+37.7%$1.85BN/A-9.1080Gap UpGPCRStructure Therapeutics3.2731 of 5 stars$30.19+0.4%$68.67+127.4%-30.7%$1.73BN/A-28.75136BHVNBiohaven3.4794 of 5 stars$15.29-3.3%$48.85+219.6%-69.8%$1.67BN/A-2.00239Gap Up Related Companies and Tools Related Companies Sarepta Therapeutics Alternatives Ocular Therapeutix Alternatives Dyne Therapeutics Alternatives ANI Pharmaceuticals Alternatives Vera Therapeutics Alternatives Tilray Brands Alternatives Twist Bioscience Alternatives Cogent Biosciences Alternatives Structure Therapeutics Alternatives Biohaven Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
